U.S. Semiconductors Stock News

NasdaqGS:MSTR
NasdaqGS:MSTRSoftware

US Stock Market Today: S&P 500 Futures Edge Higher On Surging Global Tech Demand

The Morning Bull - US Market Morning Update Monday, Feb, 9 2026 E mini S&P 500 futures are slightly higher this morning, with investors eyeing a powerful surge in global tech and chip demand. Taiwan’s exports rose 69.9% year on year in January to US$65.77b, led by electronics and information technology products. This signals strong appetite for the components that sit inside everything from smartphones to data centers. At the same time, China’s foreign exchange reserves stand at US$3.399t,...
NYSE:PBH
NYSE:PBHPharmaceuticals

How Mixed Q3 Results, Buybacks and Pillar5 Deal At Prestige (PBH) Have Changed Its Investment Story

In early February 2026, Prestige Consumer Healthcare reported third-quarter fiscal 2026 results showing lower sales and earnings, narrowed full-year revenue guidance to about US$1.10 billion, and detailed continued share repurchases and the recent Pillar5 acquisition amid supply constraints in its Clear Eyes brand. The company highlighted strong free cash flow, reduced leverage, and the flexibility to fund brand investment, selective M&A, and sizeable buybacks at the same time. With recent...
NasdaqCM:DNTH
NasdaqCM:DNTHBiotechs

How Investors Are Reacting To Dianthus Therapeutics (DNTH) US$600 Million Universal Shelf Registration

Dianthus Therapeutics, Inc. recently filed a universal shelf registration of up to US$600 million, covering common and preferred stock, debt securities, warrants and units, while also participating in the Guggenheim Emerging Outlook: Biotech Summit 2026 through a CEO fireside chat and investor meetings. This broad financing framework gives the clinical-stage biotech considerable flexibility in how and when it may access capital across different security types. Next, we will examine how the...
NasdaqGM:NRIX
NasdaqGM:NRIXBiotechs

Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration

Nurix Therapeutics (NRIX) is in focus after reporting full year 2025 earnings that paired revenue of US$83.98 million with a wider net loss of US$264.46 million, alongside a new US$98.8 million shelf registration. See our latest analysis for Nurix Therapeutics. The latest earnings release and shelf registration have arrived after a volatile stretch, with a 31.03% 90 day share price return contrasting with a 12.69% 30 day decline and a 6.44% 1 year total shareholder return fall. This suggests...